CD1-MR1 2017*
Chairs: Leonid Metelitsa & Shinichiro Motohashi
NKT cell-targeted immunotherapy for non-small cell lung cancer (#60)
1:30 PM
Immunity to the same tumor in lungs vs skin is differentially regulated by NKT cells or Treg cells and is asymmetrically cross-protective (#61)
1:50 PM
Retargeting T cells against leukemia by lipid-specific TCR transfer (#62)
2:10 PM
Investigating anti-lymphoma effects of human CD4+ iNKT cells in vivo: effectors or adjuvants? (#63)
2:30 PM
Profiling NKT cell responses in cancer patients to identify immune biomarkers (#64)
2:50 PM
Harnessing natural and engineered properties of NKT cells for adoptive cancer immunotherapy (#65)
3:10 PM